Cargando…
Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusse...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/ https://www.ncbi.nlm.nih.gov/pubmed/29255710 http://dx.doi.org/10.3389/fmed.2017.00219 |
_version_ | 1783285072236904448 |
---|---|
author | Seltsam, Axel |
author_facet | Seltsam, Axel |
author_sort | Seltsam, Axel |
collection | PubMed |
description | In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusses the relevance of PI for the field of transfusion medicine and describes the available and emerging PI technologies that can be used to treat cellular blood products such as platelet and red blood cell units. In collaboration with the French medical device manufacturer Macopharma, the German Red Cross Blood Services developed a new UVC light-based PI method for platelet units, which is currently being investigated in clinical trials. |
format | Online Article Text |
id | pubmed-5722787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57227872017-12-18 Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine Seltsam, Axel Front Med (Lausanne) Medicine In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusses the relevance of PI for the field of transfusion medicine and describes the available and emerging PI technologies that can be used to treat cellular blood products such as platelet and red blood cell units. In collaboration with the French medical device manufacturer Macopharma, the German Red Cross Blood Services developed a new UVC light-based PI method for platelet units, which is currently being investigated in clinical trials. Frontiers Media S.A. 2017-12-04 /pmc/articles/PMC5722787/ /pubmed/29255710 http://dx.doi.org/10.3389/fmed.2017.00219 Text en Copyright © 2017 Seltsam. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Seltsam, Axel Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine |
title | Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine |
title_full | Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine |
title_fullStr | Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine |
title_full_unstemmed | Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine |
title_short | Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine |
title_sort | pathogen inactivation of cellular blood products—an additional safety layer in transfusion medicine |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/ https://www.ncbi.nlm.nih.gov/pubmed/29255710 http://dx.doi.org/10.3389/fmed.2017.00219 |
work_keys_str_mv | AT seltsamaxel pathogeninactivationofcellularbloodproductsanadditionalsafetylayerintransfusionmedicine |